22 May 2013
Keywords: emselex, increases, dry, days, oab, patients, new
Article | 28 March 2005
New data presented at the European Association of Urology congress in Istanbul, Turkey, show that Novartis' Emselex/Enablex (darifenacin), a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 March 2005
21 May 2013
© 2013 thepharmaletter.com